# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-23-023075
Filing Date
2023-05-05
Accepted
2023-05-05 07:01:04
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20008400x3_defa14a.htm | DEFA14A | 15403
2 |  | ny20008400x3-nc_01.jpg | GRAPHIC | 1817577
3 |  | ny20008400x3-nc_02.jpg | GRAPHIC | 1400971
| Complete submission text file | 0001140361-23-023075.txt |  | 4136381

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-11460 | Film No.: 23891174
SIC: 2834 Pharmaceutical Preparations